Literature DB >> 3484334

Stability of 5-fluorouracil in whole blood and plasma.

R F Murphy1, F M Balis, D G Poplack.   

Abstract

We studied the stability of 5-fluorouracil (5-FU) in plasma and whole blood kept at room temperature and on ice for 1 to 24 h. At room temperature, there was a steady loss of 94% of the parent drug over 24 h in whole blood and 52% in plasma. In the presence of an excess of uracil, 5-FU was stable for 24 h, suggesting that the loss of 5-FU is the result of enzymatic degradation. 5-FU is more stable in whole blood and plasma when samples are kept cold. For blood and plasma samples maintained on ice, the loss was only 30% and 10% of the parent drug in the respective samples over 24 h. Frozen plasma samples (-20 degrees C) were stable for five weeks. Blood specimens collected for quantifying 5-FU should be immediately placed on ice, and the plasma should be separated and frozen as promptly as possible.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3484334

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  7 in total

1.  Phase II trial of sequential methotrexate and 5-fluorouracil with leucovorin in children with sarcomas.

Authors:  F M Balis; A Gillespie; J Belasco; G H Reaman; L J Ettinger; R F Murphy; K Doherty; S Jeffries; M E Horowitz; D G Poplack
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

Review 2.  Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy.

Authors:  Jan H Beumer; Edward Chu; Carmen Allegra; Yusuke Tanigawara; Gerard Milano; Robert Diasio; Tae Won Kim; Ron H Mathijssen; Li Zhang; Dirk Arnold; Katsuki Muneoka; Narikazu Boku; Markus Joerger
Journal:  Clin Pharmacol Ther       Date:  2018-09-11       Impact factor: 6.875

3.  Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients.

Authors:  S A Van Der Heyden; M S Highley; E A De Bruijn; U R Tjaden; H J Reeuwijk; H Van Slooten; A T Van Oosterom; R A Maes
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

4.  A retrospective analysis of plasma concentration monitoring of fluorouracil in patients with advanced colorectal cancer.

Authors:  Quanliang Yang; Yanzhi Bi; Xiaoqian Li; Qian Liu; Jian Ma; Chengliang Zhang; Jinlin Zhang; Guangzhao He
Journal:  Eur J Hosp Pharm       Date:  2019-03-16

5.  Relationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy.

Authors:  Maud Beneton; Sophie Chapet; Hélène Blasco; Bruno Giraudeau; Michèle Boisdron-Celle; Régine Deporte-Fety; Fabrice Denis; Bérangère Narcisso; Gilles Calais; Chantal Le Guellec
Journal:  Br J Clin Pharmacol       Date:  2007-06-19       Impact factor: 4.335

Review 6.  Therapeutic drug monitoring of 5-fluorouracil.

Authors:  James J Lee; Jan H Beumer; Edward Chu
Journal:  Cancer Chemother Pharmacol       Date:  2016-05-23       Impact factor: 3.333

7.  Human in vitro vascularized micro-organ and micro-tumor models are reproducible organ-on-a-chip platforms for studies of anticancer drugs.

Authors:  Yizhong Liu; Courtney Sakolish; Zunwei Chen; Duc T T Phan; R Hugh F Bender; Christopher C W Hughes; Ivan Rusyn
Journal:  Toxicology       Date:  2020-09-24       Impact factor: 4.221

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.